---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-020731"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:13:53.007477+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Dyadic posts strategic presentation; no specific financial or operational updates

## Summary
- Presentation posted July 23, 2025 highlights transition from research to commercial focus.
- Focus on C1 and Dapibus gene expression platforms for non-therapeutic protein production.
- No specific financial targets, revenue guidance, or operational metrics disclosed.
- Presentation will be used at industry and investor conferences.

## SEC filing metadata
- accession: 0001641172-25-020731
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000164117225020731/0001641172-25-020731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000164117225020731/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-020731
- JSON: https://secwatch.observer/filing/0001641172-25-020731.json
- Plain text: https://secwatch.observer/filing/0001641172-25-020731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.